Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

123.37USD
22 Mar 2017
Change (% chg)

-- (--)
Prev Close
$123.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,570,420
52-wk High
$127.64
52-wk Low
$94.42

Select another date:

Thu, Mar 16 2017

BRIEF-Oncolytics Biotech enters collaboration with Myeloma UK and Celgene

* Oncolytics biotech enters into first-in-class collaboration with Myeloma UK and Celgene using Reolysin in combination with Imnovid or Revlimid in patients with Myeloma

BRIEF-Alliqua Biomedical says co and Celgene entered into side letter agreement

* On March 13, 2017, co and Celgene entered into a side letter agreement - sec filing

BRIEF-Agios Pharmaceuticals announces MTAP pathway research program and collaboration agreement with Celgene

* Agios announces MTAP pathway research program as development program and development candidate under master research and collaboration agreement with Celgene

Celgene, whistleblower pursuing mediation in off-label marketing case

Celgene Corp and a whistleblower who brought a lawsuit accusing it of promoting its cancer drugs Revlimid and Thalomid for off-label uses have asked the judge presiding over the case not to issue any substantive rulings for 30 days while they pursue mediation.

BRIEF-Celgene announces retirement of president and COO Jacqualyn Fouse

* Celgene announces retirement of president and Chief Operating Officer, Jacqualyn Fouse, Ph.D. And promotion of Scott Smith to president and chief operating officer Source text for Eikon: Further company coverage:

BRIEF-FDA expands indication for Revlimid in multiple myeloma patients following auto-HSCT

* FDA expands indication for Revlimid® (lenalidomide) as a maintenance treatment for patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT)

BRIEF-Celgene reports positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis

* Celgene announces positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis

Celgene to pay $198.5 million to settle drug patent licensing case

Biopharmaceutical company Celgene Corp has agreed to pay $198.5 million to resolve a lawsuit accusing it of failing to pay royalties on patents for two drugs subject to a licensing agreement.

BRIEF-Soros Fund Management takes in Facebook, ups in T Mobile and Alphabet

* Soros Fund Management takes share stake in facebook inc of 353,686 shares

BRIEF-Neximmune acquired by group of investors led by former Celgene and Medtronic CEOs

* Acquired by a consortium of private investors led by former Celgene and Medtronic ceos Source text for Eikon:

Select another date:

More From Around the Web